SynthesisFrontiers in radiology2025
Comparative analysis of white matter signal alterations in dementia with Lewy bodies and Alzheimer's disease: a systematic review and meta-analysis.
Synthesis in Frontiers in radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comorbid Pathologies and Their Impact on Dementia with Lewy Bodies-Current View.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Lewy body diseases (LBD) include neurodegenerative diseases such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and Parkinson's disease dementia (PDD). Because DLB and Alzheimer's disease (AD) share similar neurological symptoms, DLB is frequently underdiagnosed. White Matter Hyperintensities (WMH) are associated with dementia risk and changes in both DLB and AD. In order to examine WMH discrepancies in DLB and AD patients and gain insight into their diagnostic utility and pathophysiological significance, this systematic review and meta-analysis is conducted. Material and methods: Databases such as PubMed, Scopus, Google Scholar, and Web of Science were searched for studies reporting WMH in DLB and AD patients based on Preferred Reporting Items for Systematic Review (PRISMA) guideline. Stata version 15 US is used to analyze the extracted data. Results: Twelve studies with 906 AD and 499 DLB patients were considered in this analysis. Although not statistically significant, the WMH was 0.03 ml larger in AD patients than in DLB patients. The prevalence of hypertension varied, ranging from 21% to 56% in DLB patients and from 30% to 52% in AD patients. Different findings were found on the prevalence of diabetes; some research suggested that DLB patients had greater rates (18.7%-37%) than AD patients (9%-17.5%). The imaging modalities FLAIR, T2-weighted, and T1-weighted sequences were employed. Compared to DLB patients, AD patients had higher cortical and infratentorial infarcts. Conclusion: Those with AD have greater WMH volumes than cases with DLB, suggesting that WMH can be a biomarker to help better differentiation between these neurodegenerative diseases; however, this difference is not significant. To better understand the therapeutic implications and options for reducing WMH-related cognitive loss in various patient populations, more research is necessary.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.